
Albireo Pharma ALBO
Quartalsbericht 2022-Q3
hinzugefügt 08.11.2022
Albireo Pharma Langfristige Verbindlichkeiten 2011-2026 | ALBO
Langfristige Verbindlichkeiten Jährlich Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | 79.1 M | 53 M | 50 M | 42 K | 359 K | 59 K | 1.01 M | 6.15 M | 7.34 M | 1.14 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 79.1 M | 42 K | 19.8 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Cabaletta Bio
CABA
|
43.9 M | $ 3.33 | 2.15 % | $ 335 M | ||
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
1.19 M | $ 3.07 | 0.49 % | $ 5.05 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
604 M | $ 332.58 | -2.01 % | $ 43.6 B | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alterity Therapeutics Limited
ATHE
|
73.6 K | $ 3.8 | 4.97 % | $ 9.14 B | ||
|
AlloVir
ALVR
|
5.46 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Aligos Therapeutics
ALGS
|
15 M | $ 7.51 | -14.07 % | $ 74.2 M | ||
|
Allakos
ALLK
|
8.11 M | - | - | $ 28.6 M | ||
|
Esperion Therapeutics
ESPR
|
355 M | $ 2.11 | 2.77 % | $ 439 M | ||
|
Evogene Ltd.
EVGN
|
5.36 M | $ 0.82 | - | $ 27.9 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
106 M | - | - | $ 10.1 M | ||
|
Forte Biosciences
FBRX
|
10.5 M | $ 32.35 | -0.2 % | $ 419 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
Applied Therapeutics
APLT
|
797 K | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
114 K | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
10.2 M | - | -13.39 % | $ 1.45 M | ||
|
Galapagos NV
GLPG
|
2.41 B | $ 28.99 | 0.36 % | $ 2.69 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 21.36 | -0.09 % | $ 998 M | ||
|
Genmab A/S
GMAB
|
769 M | $ 29.02 | -0.14 % | $ 18.6 B | ||
|
GT Biopharma
GTBP
|
714 K | $ 0.38 | -3.34 % | $ 2.1 M | ||
|
BioNTech SE
BNTX
|
341 M | $ 99.43 | 1.03 % | $ 27.2 B | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Hoth Therapeutics
HOTH
|
2.71 K | $ 0.68 | 4.58 % | $ 9.39 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
Harmony Biosciences Holdings
HRMY
|
149 M | $ 29.37 | 0.27 % | $ 1.69 B | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
ImmuCell Corporation
ICCC
|
11.5 M | $ 7.61 | -1.55 % | $ 68.7 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
168 M | $ 1.54 | -1.28 % | $ 396 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
Aquestive Therapeutics
AQST
|
90.3 M | $ 4.18 | 0.6 % | $ 447 M | ||
|
Arcutis Biotherapeutics
ARQT
|
167 M | $ 24.39 | -2.79 % | $ 3.1 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
618 K | - | -2.5 % | $ 5.88 M | ||
|
AIkido Pharma
AIKI
|
2.29 M | - | 1.93 % | $ 17.4 M | ||
|
Incyte Corporation
INCY
|
315 M | $ 97.43 | -0.27 % | $ 19 B | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.46 | -1.49 % | $ 389 M | ||
|
Aptose Biosciences
APTO
|
27.9 M | - | -45.71 % | $ 1.2 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
Innate Pharma S.A.
IPHA
|
105 M | $ 1.71 | 4.91 % | $ 235 M |